A review and outlook in the treatment of osteosarcoma and other deep tumors with photodynamic therapy: From basic to deep

Oncotarget

Volumn 8, Issue 24, 2017, Pages 39833-39848

  Yu, Wei ^a,b   Zhu, Jian ^a,b   Wang, Yitian ^a,b   Wang, Junjie ^a,b   Fang, Weijing ^a,b   Xia, Kaishun ^a,b   Shao, Jianlin ^c   Wu, Minzu ^d   Liu, Bing ^a,b   Liang, Chengzhen ^a,b   Ye, Chengyi ^a,b   Tao, Huimin ^a,b  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b The Architectural Design Research Institute of Zhejiang University Co   (China)

^c LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^d SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

Author keywords

Immunotherapy; Nanotechnology; Osteosarcoma; Photodynamic; Target therapy

Indexed keywords

AUTOPHAGY RELATED PROTEIN 5; CALRETICULIN; CD39 ANTIGEN; CD79 ANTIGEN; CYCLOOXYGENASE 2; GLASS FIBER; HEAT SHOCK PROTEIN 70; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; MIFAMURTIDE; PROTOPORPHYRIN; PURINERGIC P2X7 RECEPTOR; REACTIVE OXYGEN METABOLITE; TOLL LIKE RECEPTOR 4; VASCULOTROPIN; PHOTOSENSITIZING AGENT;

ANGIOGENESIS; APOPTOSIS; AUTOPHAGY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER RISK; CELL CYCLE G0 PHASE; CELL VIABILITY; CYTOTOXICITY; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NEAR INFRARED SPECTROSCOPY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOSARCOMA; OXIDATIVE STRESS; PHOTODYNAMIC THERAPY; REVIEW; S PHASE CELL CYCLE CHECKPOINT; ANIMAL; BONE TUMOR; PATHOLOGY; PHOTOCHEMOTHERAPY; PROCEDURES; TREATMENT OUTCOME;

ANIMALS; BONE NEOPLASMS; HUMANS; OSTEOSARCOMA; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; TREATMENT OUTCOME;

EID: 85020634780     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.16243     Document Type: Review

References (152)

1. Ritter J, Bielack SS. Osteosarcoma. Ann Oncol. 2010; 21 Suppl 7:vii320-325
2. Aponte-Tinao L, Ayerza MA, Muscolo DL, Farfalli GL. Survival, recurrence, and function after epiphyseal preservation and allograft reconstruction in osteosarcoma of the knee. Clin Orthop Relat Res. 2015; 473:1789-1796
3. Anderson ME. Update on Survival in Osteosarcoma. Orthop Clin North Am. 2016; 47:283-292
4. Ta HT, Dass CR, Choong PF, Dunstan DE. Osteosarcoma treatment: state of the art. Cancer Metastasis Rev. 2009; 28:247-263
5. Tiwari A. Current concepts in surgical treatment of osteosarcoma. J Clin Orthop Trauma. 2012; 3:4-9
6. Horie T, Ono K, Nishi H, Nagao K, Kinoshita M, Watanabe S, Kuwabara Y, Nakashima Y, Takanabe-Mori R, Nishi E, Hasegawa K, Kita T, Kimura T. Acute doxorubicin cardiotoxicity is associated with miR-146a-induced inhibition of the neuregulin-ErbB pathway. Cardiovasc Res. 2010; 87:656-664
7. Isakoff MS, Bielack SS, Meltzer P, Gorlick R. Osteosarcoma: Current Treatment and a Collaborative Pathway to Success. J Clin Oncol. 2015; 33(27):3029-3035
8. Canter RJ. Chemotherapy: Does Neoadjuvant or Adjuvant Therapy Improve Outcomes? Surg Oncol Clin N Am. 2016; 25:861-872
9. Agostinis P, Berg K, Cengel KA, Foster TH, Girotti AW, Gollnick SO, Hahn SM, Hamblin MR, Juzeniene A, Kessel D, Korbelik M, Moan J, Mroz P, et al. Photodynamic therapy of cancer: an update. CA Cancer J Clin. 2011; 61:250-281
10. St Denis TG, Hamblin MR. Synthesis, bioanalysis and biodistribution of photosensitizer conjugates for photodynamic therapy. Bioanalysis. 2013; 5:1099-1114
11. Cheng L, Wang C, Feng L, Yang K and Liu Z. Functional nanomaterials for phototherapies of cancer. Chem Rev. 2014; 114:10869-10939
12. Kamkaew A, Chen F, Zhan Y, Majewski RL, Cai W. Scintillating Nanoparticles as Energy Mediators for Enhanced Photodynamic Therapy. ACS Nano. 2016; 10:3918-3935
13. Abrahamse H, Hamblin MR. New photosensitizers for photodynamic therapy. Biochem J. 2016; 473:347-364
14. Sun M, Zhou C, Zeng H, Puebla-Osorio N, Damiani E, Chen J, Wang H, Li G, Yin F, Shan L, Zuo D, Liao Y, Wang Z, et al. Hiporfin-mediated photodynamic therapy in preclinical treatment of osteosarcoma. Photochem Photobiol. 2015; 91:533-544
15. Meier D, Campanile C, Botter SM, Born W, Fuchs B. Cytotoxic efficacy of photodynamic therapy in osteosarcoma cells in vitro. J Vis Exp. 2014
16. Reidy K, Campanile C, Muff R, Born W, Fuchs B. mTHPC-mediated photodynamic therapy is effective in the metastatic human 143B osteosarcoma cells. Photochem Photobiol. 2012; 88:721-727
17. Peng Q, Berg K, Moan J, Kongshaug M, Nesland JM. 5-Aminolevulinic acid-based photodynamic therapy: principles and experimental research. Photochem Photobiol. 1997; 65:235-251
18. White B, Rossi V, Baugher PJ. Aminolevulinic Acid-Mediated Photodynamic Therapy Causes Cell Death in MG-63 Human Osteosarcoma Cells. Photomed Laser Surg. 2016; 34:400-405
19. Huang Y, Xu G, Peng Y, Lin H, Zheng X, Xie M. Zinc phthalocyanine tetrasulfonate (ZnPcS4): a new photosensitizer for photodynamic therapy in choroidal neovascularization. J Ocul Pharmacol Ther. 2007; 23:377-386
20. Ongarora BG, Hu X, Verberne-Sutton SD, Garno JC, Vicente MG. Syntheses and Photodynamic Activity of Pegylated Cationic Zn(II)-Phthalocyanines in HEp2 Cells. Theranostics. 2012; 2:850-870
21. Feuser PE, Gaspar PC, Jacques AV, Tedesco AC, dos Santos Silva MC, Ricci-Junior E, Sayer C, de Araujo PH. Synthesis of ZnPc loaded poly(methyl methacrylate) nanoparticles via miniemulsion polymerization for photodynamic therapy in leukemic cells. Mater Sci Eng C Mater Biol Appl. 2016; 60:458-466
22. Gao W, Wang Z, Lv L, Yin D, Chen D, Han Z, Ma Y, Zhang M, Yang M, Gu Y. Photodynamic Therapy Induced Enhancement of Tumor Vasculature Permeability Using an Upconversion Nanoconstruct for Improved Intratumoral Nanoparticle Delivery in Deep Tissues. Theranostics. 2016; 6:1131-1144
23. Jin CS, Cui L, Wang F, Chen J, Zheng G. Targetingtriggered porphysome nanostructure disruption for activatable photodynamic therapy. Adv Healthc Mater. 2014; 3:1240-1249
24. Allison RR. Photodynamic therapy: oncologic horizons. Future Oncol. 2014; 10:123-124
25. Dolmans DE, Fukumura D, Jain RK. Photodynamic therapy for cancer. Nat Rev Cancer. 2003; 3:380-387
26. Allison RR, Mota HC, Sibata CH. Clinical PD/PDT in North America: An historical review. Photodiagnosis Photodyn Ther. 2004; 1:263-277
27. Tsai SR, Yin R, Huang YY, Sheu BC, Lee SC, Hamblin MR. Low-level light therapy potentiates NPe6-mediated photodynamic therapy in a human osteosarcoma cell line via increased ATP. Photodiagnosis Photodyn Ther. 2015; 12:123-130
28. Guan J, Lai X, Wang X, Leung AW, Zhang H, Xu C. Photodynamic action of methylene blue in osteosarcoma cells in vitro. Photodiagnosis Photodyn Ther. 2014; 11:13-19
29. Foote CS. Definition of type I and type II photosensitized oxidation. Photochem Photobiol. 1991; 54:659
30. Oniszczuk A, Wojtunik-Kulesza KA, Oniszczuk T, Kasprzak K. The potential of photodynamic therapy (PDT)-Experimental investigations and clinical use. Biomed Pharmacother. 2016; 83:912-929
31. Romiszewska A, Nowak-Stepniowska A. [Photodynamic reaction and oxidative stress-influence of the photodynamic effect on the activity antioxidant enzymes]. Postepy Biochem. 2014; 60:355-364
32. Ogbodu RO, Nyokong T. The effect of ascorbic acid on the photophysical properties and photodynamic therapy activities of zinc phthalocyanine-single walled carbon nanotube conjugate on MCF-7 cancer cells. Spectrochim Acta A Mol Biomol Spectrosc. 2015; 151:174-183
33. Cheng Y, Cheng H, Jiang C, Qiu X, Wang K, Huan W, Yuan A, Wu J, Hu Y. Perfluorocarbon nanoparticles enhance reactive oxygen levels and tumour growth inhibition in photodynamic therapy. Nat Commun. 2015; 6:8785
34. Li KT, Chen Q, Wang DW, Duan QQ, Tian S, He JW, Ou YS, Bai DQ. Mitochondrial pathway and endoplasmic reticulum stress participate in the photosensitizing effectiveness of AE-PDT in MG63 cells. Cancer Med. 2016; 5:3186-3193
35. Tu P, Huang Q, Ou Y, Du X, Li K, Tao Y, Yin H. Aloeemodin-mediated photodynamic therapy induces autophagy and apoptosis in human osteosarcoma cell line MG63 through the ROS/JNK signaling pathway. Oncol Rep. 2016; 35:3209-3215
36. Huang Q, Ou YS, Tao Y, Yin H, Tu PH. Apoptosis and autophagy induced by pyropheophorbide-alpha methyl ester-mediated photodynamic therapy in human osteosarcoma MG-63 cells. Apoptosis. 2016; 21:749-760
37. Matsubara T, Diresta GR, Kakunaga S, Li D, Healey JH. Additive Influence of Extracellular pH, Oxygen Tension, and Pressure on Invasiveness and Survival of Human Osteosarcoma Cells. Front Oncol. 2013; 3:199
38. Cheung KK, Chan JY, Fung KP. Antiproliferative effect of pheophorbide α-mediated photodynamic therapy and its synergistic effect with doxorubicin on multiple drugresistant uterine sarcoma cell MES-SA/Dx5. Drug Chem Toxicol. 2013; 36:474-483
39. 2 inorganic photosensitizers for NIR-triggered photodynamic therapy and enhanced chemotherapy in drug-resistant breast cancers. Biomaterials. 2015; 57:93-106
40. Yamauchi M, Honda N, Hazama H, Tachikawa S, Nakamura H, Kaneda Y, Awazu K. A novel photodynamic therapy for drug-resistant prostate cancer cells using porphyrus envelope as a novel photosensitizer. Photodiagnosis Photodyn Ther. 2014; 11:48-54
41. Lindsay J, Esposti MD, Gilmore AP. Bcl-2 proteins and mitochondria-specificity in membrane targeting for death. Biochim Biophys Acta. 2011; 1813:532-539
42. Goler-Baron V, Assaraf YG. Overcoming multidrug resistance via photodestruction of ABCG2-rich extracellular vesicles sequestering photosensitive chemotherapeutics. PLoS One. 2012; 7:e35487
43. Chen B, Pogue BW, Hoopes PJ, Hasan T. Combining vascular and cellular targeting regimens enhances the efficacy of photodynamic therapy. Int J Radiat Oncol Biol Phys. 2005; 61:1216-1226
44. Barathan M, Mariappan V, Shankar EM, Abdullah BJ, Goh KL, Vadivelu J. Hypericin-photodynamic therapy leads to interleukin-6 secretion by HepG2 cells and their apoptosis via recruitment of BH3 interacting-domain death agonist and caspases. Cell Death Dis. 2013; 4:e697
45. Snyder JW, Greco WR, Bellnier DA, Vaughan L, Henderson BW. Photodynamic therapy: a means to enhanced drug delivery to tumors. Cancer Res. 2003; 63:8126-8131
46. Wang D, Wang T, Liu J, Yu H, Jiao S, Feng B, Zhou F, Fu Y, Yin Q, Zhang P, Zhang Z, Zhou Z, Li Y. Acid-Activatable Versatile Micelleplexes for PD-L1 Blockade-Enhanced Cancer Photodynamic Immunotherapy. Nano Lett. 2016; 16:5503-5513
47. Kusuzaki K, Minami G, Takeshita H, Murata H, Hashiguchi S, Nozaki T, Ashihara T, Hirasawa Y. Photodynamic inactivation with acridine orange on a multidrug-resistant mouse osteosarcoma cell line. Jpn J Cancer Res. 2000; 91:439-445
48. 2 nanocomposites for magnetic resonance imaging and potential photodynamic therapy. Nanoscale. 2013; 5:2107-2113
49. Ma X, Qu Q, Zhao Y. Targeted delivery of 5-aminolevulinic acid by multifunctional hollow mesoporous silica nanoparticles for photodynamic skin cancer therapy. ACS Appl Mater Interfaces. 2015; 7:10671-10676
50. Hirohara S, Oka C, Totani M, Obata M, Yuasa J, Ito H, Tamura M, Matsui H, Kakiuchi K, Kawai T, Kawaichi M, Tanihara M. Synthesis, Photophysical Properties, and Biological Evaluation of trans-Bisthioglycosylated Tetrakis(fluorophenyl)chlorin for Photodynamic Therapy. J Med Chem. 2015; 58:8658-8670
51. Muhanna N, Cui L, Chan H, Burgess L, Jin CS, MacDonald TD, Huynh E, Wang F, Chen J, Irish JC, Zheng G. Multimodal Image-Guided Surgical and Photodynamic Interventions in Head and Neck Cancer: From Primary Tumor to Metastatic Drainage. Clin Cancer Res. 2016; 22:961-970
52. Vera RE, Lamberti MJ, Rivarola VA, Rumie Vittar NB. Developing strategies to predict photodynamic therapy outcome: the role of melanoma microenvironment. Tumour Biol. 2015; 36:9127-9136
53. Hu J, Tang Y, Elmenoufy AH, Xu H, Cheng Z, Yang X. Nanocomposite-Based Photodynamic Therapy Strategies for Deep Tumor Treatment. Small. 2015; 11:5860-5887
54. Vijayaraghavan P, Vankayala R, Chiang CS, Sung HW, Hwang KC. Complete destruction of deep-tissue buried tumors via combination of gene silencing and gold nanoechinus-mediated photodynamic therapy. Biomaterials. 2015; 62:13-23
55. Fotia C, Avnet S, Kusuzaki K, Roncuzzi L, Baldini N. Acridine Orange is an Effective Anti-Cancer Drug that Affects Mitochondrial Function in Osteosarcoma Cells. Curr Pharm Des. 2015; 21:4088-4094
56. Satonaka H, Kusuzaki K, Akeda K, Tsujii M, Iino T, Uemura T, Matsubara T, Nakamura T, Asanuma K, Matsumine A, Sudo A. Acridine orange inhibits pulmonary metastasis of mouse osteosarcoma. Anticancer Res. 2011; 31:4163-4168
57. Yanase S, Nomura J, Matsumura Y, Nagata T, Fujii T, Tagawa T. Synergistic interaction of 5-aminolevulinic acid-based photodynamic therapy with simultaneous hyperthermia in an osteosarcoma tumor model. Int J Oncol. 2006; 29:365-373
58. Coupienne I, Fettweis G, Piette J. RIP3 expression induces a death profile change in U2OS osteosarcoma cells after 5-ALA-PDT. Lasers Surg Med. 2011; 43:557-564
59. Lee HB, Ho AS and Teo SH. p53 Status does not affect photodynamic cell killing induced by hypericin. Cancer Chemother Pharmacol. 2006; 58:91-98
60. Matsubara T, Kusuzaki K, Matsumine A, Satonaka H, Shintani K, Nakamura T, Uchida A. Methylene blue in place of acridine orange as a photosensitizer in photodynamic therapy of osteosarcoma. In Vivo. 2008; 22:297-303
61. Scherz-Shouval R, Shvets E, Fass E, Shorer H, Gil L and Elazar Z. Reactive oxygen species are essential for autophagy and specifically regulate the activity of Atg4. EMBO J. 2007; 26:1749-1760
62. Duan P, Hu C, Quan C, Yu T, Zhou W, Yuan M, Shi Y, Yang K. 4-Nonylphenol induces apoptosis, autophagy and necrosis in Sertoli cells: Involvement of ROS-mediated AMPK/AKT-mTOR and JNK pathways. Toxicology. 2016; 341-343:28-40
63. Li X, Zhu F, Jiang J, Sun C, Wang X, Shen M, Tian R, Shi C, Xu M, Peng F, Guo X, Wang M, Qin R. Synergistic antitumor activity of withaferin A combined with oxaliplatin triggers reactive oxygen species-mediated inactivation of the PI3K/AKT pathway in human pancreatic cancer cells. Cancer Lett. 2015; 357:219-230
64. Shao FY, Du ZY, Ma DL, Chen WB, Fu WY, Ruan BB, Rui W, Zhang JX, Wang S, Wong NS, Xiao H, Li MM, Liu X, et al. B5, a thioredoxin reductase inhibitor, induces apoptosis in human cervical cancer cells by suppressing the thioredoxin system, disrupting mitochondrion-dependent pathways and triggering autophagy. Oncotarget. 2015; 6:30939-30956. doi: 10.18632/oncotarget.5132
65. Ramachandran A, McGill MR, Xie Y, Ni HM, Ding WX, Jaeschke H. Receptor interacting protein kinase 3 is a critical early mediator of acetaminophen-induced hepatocyte necrosis in mice. Hepatology. 2013; 58:2099-2108
66. Schenk B, Fulda S. Reactive oxygen species regulate Smac mimetic/TNFalpha-induced necroptotic signaling and cell death. Oncogene. 2015; 34:5796-5806
67. Frame FM, Savoie H, Bryden F, Giuntini F, Mann VM, Simms MS, Boyle RW, Maitland NJ. Mechanisms of growth inhibition of primary prostate epithelial cells following gamma irradiation or photodynamic therapy include senescence, necrosis, and autophagy, but not apoptosis. Cancer Med. 2016; 5:61-73
68. Blazquez-Castro A, Carrasco E, Calvo MI, Jaen P, Stockert JC, Juarranz A, Sanz-Rodriguez F, Espada J. Protoporphyrin IX-dependent photodynamic production of endogenous ROS stimulates cell proliferation. Eur J Cell Biol. 2012; 91:216-223
69. Zorov DB, Juhaszova M, Sollott SJ. Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release. Physiol Rev. 2014; 94:909-950
70. Shao J, Xue J, Dai Y, Liu H, Chen N, Jia L, Huang J. Inhibition of human hepatocellular carcinoma HepG2 by phthalocyanine photosensitiser PHOTOCYANINE: ROS production, apoptosis, cell cycle arrest. Eur J Cancer. 2012; 48:2086-2096
71. Vantieghem A, Xu Y, Assefa Z, Piette J, Vandenheede JR, Merlevede W, De Witte PA, Agostinis P. Phosphorylation of Bcl-2 in G2/M phase-arrested cells following photodynamic therapy with hypericin involves a CDK1-mediated signal and delays the onset of apoptosis. J Biol Chem. 2002; 277:37718-37731
72. Liu J, Zheng L, Li Y, Zhang Z, Zhang L, Shen L, Zhang X, Qiao H. Effect of DTPP-mediated photodynamic therapy on cell morphology, viability, cell cycle, and cytotoxicity in a murine lung adenocarcinoma cell line. Lasers Med Sci. 2015; 30:181-191
73. Tan H, Gao S, Zhuang Y, Dong Y, Guan W, Zhang K, Xu J, Cui J. R-Phycoerythrin Induces SGC-7901 Apoptosis by Arresting Cell Cycle at S Phase. Mar Drugs. 2016; 14
74. Cook KM, Figg WD. Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J Clin. 2010; 60:222-243
75. Middelburg TA, de Bruijn HS, Tettero L, van der Ploeg van den Heuvel A, Neumann HA, de Haas ER, Robinson DJ. Topical hexylaminolevulinate and aminolevulinic acid photodynamic therapy: complete arteriole vasoconstriction occurs frequently and depends on protoporphyrin IX concentration in vessel wall. J Photochem Photobiol B. 2013; 126:26-32
76. Middelburg TA, de Vijlder HC, de Bruijn HS, van der Ploeg-van den Heuvel A, Neumann HA, de Haas ER, Robinson DJ. Topical photodynamic therapy using different porphyrin precursors leads to differences in vascular photosensitization and vascular damage in normal mouse skin. Photochem Photobiol. 2014; 90:896-902
77. van Leeuwen-van Zaane F, de Bruijn HS, van der Ploeg-van den Heuvel A, Sterenborg HJ, Robinson DJ. The effect of fluence rate on the acute response of vessel diameter and red blood cell velocity during topical 5-aminolevulinic acid photodynamic therapy. Photodiagnosis Photodyn Ther. 2014; 11:71-81
78. Choi J, Kim WJ, Park SW, Xu L, Kim SH, Min HS, Kwon GY, Cho CH, Kim S, Choi TH. Photodynamic therapy suppresses tumor growth in an in vivo model of human hemangioma. Arch Dermatol Res. 2014; 306:81-91
79. Weijer R, Broekgaarden M, Krekorian M, Alles LK, van Wijk AC, Mackaaij C, Verheij J, van der Wal AC, van Gulik TM, Storm G, Heger M. Inhibition of hypoxia inducible factor 1 and topoisomerase with acriflavine sensitizes perihilar cholangiocarcinomas to photodynamic therapy. Oncotarget. 2016; 7:3341-3356. doi: 10.18632/oncotarget.6490
80. Zhen Z, Tang W, Chuang YJ, Todd T, Zhang W, Lin X, Niu G, Liu G, Wang L, Pan Z, Chen X, Xie J. Tumor vasculature targeted photodynamic therapy for enhanced delivery of nanoparticles. ACS Nano. 2014; 8:6004-6013
81. Wang Y, Gonzalez M, Cheng C, Haouala A, Krueger T, Peters S, Decosterd LA, van den Bergh H, Perentes JY, Ris HB, Letovanec I, Debefve E. Photodynamic induced uptake of liposomal doxorubicin to rat lung tumors parallels tumor vascular density. Lasers Surg Med. 2012; 44:318-324
82. Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2013; 31:51-72
83. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T, Casares N, Metivier D, Larochette N, van Endert P, Ciccosanti F, Piacentini M, Zitvogel L, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2007; 13:54-61
84. Martins I, Wang Y, Michaud M, Ma Y, Sukkurwala AQ, Shen S, Kepp O, Metivier D, Galluzzi L, Perfettini JL, Zitvogel L, Kroemer G. Molecular mechanisms of ATP secretion during immunogenic cell death. Cell Death Differ. 2014; 21:79-91
85. Werthmoller N, Frey B, Wunderlich R, Fietkau R, Gaipl US. Modulation of radiochemoimmunotherapy-induced B16 melanoma cell death by the pan-caspase inhibitor zVAD-fmk induces anti-tumor immunity in a HMGB1-, nucleotide-and T-cell-dependent manner. Cell Death Dis. 2015; 6:e1761
86. Gardai SJ, McPhillips KA, Frasch SC, Janssen WJ, Starefeldt A, Murphy-Ullrich JE, Bratton DL, Oldenborg PA, Michalak M, Henson PM. Cell-surface calreticulin initiates clearance of viable or apoptotic cells through transactivation of LRP on the phagocyte. Cell. 2005; 123:321-334
87. Li D, Li L, Li P, Li Y, Chen X. Apoptosis of HeLa cells induced by a new targeting photosensitizer-based PDT via a mitochondrial pathway and ER stress. Onco Targets Ther. 2015; 8:703-711
88. Garg AD, Agostinis P. ER stress, autophagy and immunogenic cell death in photodynamic therapy-induced anti-cancer immune responses. Photochem Photobiol Sci. 2014; 13:474-487
89. Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C, Vermaelen K, Panaretakis T, Mignot G, Ullrich E, Perfettini JL, Schlemmer F, Tasdemir E, et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med. 2009; 15:1170-1178
90. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P, Yang H, Amigorena S, Ryffel B, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007; 13:1050-1059
91. Salimu J, Spary LK, Al-Taei S, Clayton A, Mason MD, Staffurth J, Tabi Z. Cross-Presentation of the Oncofetal Tumor Antigen 5T4 from Irradiated Prostate Cancer Cells-A Key Role for Heat-Shock Protein 70 and Receptor CD91. Cancer Immunol Res. 2015; 3:678-688
92. Garg AD, Dudek AM, Ferreira GB, Verfaillie T, Vandenabeele P, Krysko DV, Mathieu C, Agostinis P. ROS-induced autophagy in cancer cells assists in evasion from determinants of immunogenic cell death. Autophagy. 2013; 9:1292-1307
93. Shaif-Muthana M, McIntyre C, Sisley K, Rennie I, Murray A. Dead or alive: immunogenicity of human melanoma cells when presented by dendritic cells. Cancer Res. 2000; 60:6441-6447
94. Zitvogel L, Casares N, Pequignot MO, Chaput N, Albert ML, Kroemer G. Immune response against dying tumor cells. Adv Immunol. 2004; 84:131-179
95. d'Almeida SM, Kauffenstein G, Roy C, Basset L, Papargyris L, Henrion D, Catros V, Ifrah N, Descamps P, Croue A, Jeannin P, Gregoire M, Delneste Y, Tabiasco J. The ecto-ATPDase CD39 is involved in the acquisition of the immunoregulatory phenotype by M-CSF-macrophages and ovarian cancer tumor-associated macrophages: Regulatory role of IL-27. Oncoimmunology. 2016; 5:e1178025
96. Stagg J, Beavis PA, Divisekera U, Liu MC, Moller A, Darcy PK, Smyth MJ. CD73-deficient mice are resistant to carcinogenesis. Cancer Res. 2012; 72:2190-2196
97. Kawano M, Tanaka K, Itonaga I, Iwasaki T, Miyazaki M, Ikeda S, Tsumura H. Dendritic cells combined with doxorubicin induces immunogenic cell death and exhibits antitumor effects for osteosarcoma. Oncol Lett. 2016; 11:2169-2175
98. Yanase S, Nomura J, Matsumura Y, Nagai K, Kinoshita M, Nakanishi H, Ohnishi Y, Tokuda T, Tagawa T. Enhancement of the effect of 5-aminolevulinic acid-based photodynamic therapy by simultaneous hyperthermia. Int J Oncol. 2005; 27:193-201
99. Guix M, Mayorga-Martinez CC, Merkoci A. Nano/micromotors in (bio)chemical science applications. Chem Rev. 2014; 114:6285-6322
100. Nishiyama N, Okazaki S, Cabral H, Miyamoto M, Kato Y, Sugiyama Y, Nishio K, Matsumura Y, Kataoka K. Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice. Cancer Res. 2003; 63:8977-8983
101. Uchino H, Matsumura Y, Negishi T, Koizumi F, Hayashi T, Honda T, Nishiyama N, Kataoka K, Naito S, Kakizoe T. Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats. Br J Cancer. 2005; 93:678-687
102. Liu P, Sun L, Zhou DS, Zhang P, Wang YH, Li D, Li QH, Feng RJ. Retraction: Development of Alendronateconjugated Poly (lactic-co-glycolic acid)-Dextran Nanoparticles for Active Targeting of Cisplatin in Osteosarcoma. Sci Rep. 2016; 6:31938
103. 3 nanoparticles as an ultra-sensitive tumorpH-responsive nanoplatform enabling real-time drug release monitoring and cancer combination therapy. Biomaterials. 2016; 110:60-70
104. Broekgaarden M, van Vught R, Oliveira S, Roovers RC, van Bergen en Henegouwen PM, Pieters RJ, Van Gulik TM, Breukink E, Heger M. Site-specific conjugation of single domain antibodies to liposomes enhances photosensitizer uptake and photodynamic therapy efficacy. Nanoscale. 2016; 8:6490-6494
105. Croy SR, Kwon GS. Polymeric micelles for drug delivery. Curr Pharm Des. 2006; 12:4669-4684
106. Hung HI, Klein OJ, Peterson SW, Rokosh SR, Osseiran S, Nowell NH, Evans CL. PLGA nanoparticle encapsulation reduces toxicity while retaining the therapeutic efficacy of EtNBS-PDT in vitro. Sci Rep. 2016; 6:33234
107. Ku EB, Lee DJ, Na K, Choi SW, Youn YS, Bae SK, Oh KT, Lee ES. pH-Responsive globular poly(ethylene glycol) for photodynamic tumor therapy. Colloids Surf B Biointerfaces. 2016; 148:173-180
108. Teng IT, Chang YJ, Wang LS, Lu HY, Wu LC, Yang CM, Chiu CC, Yang CH, Hsu SL, Ho JA. Phospholipidfunctionalized mesoporous silica nanocarriers for selective photodynamic therapy of cancer. Biomaterials. 2013; 34:7462-7470
109. Seidl C, Ungelenk J, Zittel E, Bergfeldt T, Sleeman JP, Schepers U, Feldmann C. Tin Tungstate Nanoparticles: A Photosensitizer for Photodynamic Tumor Therapy. ACS Nano. 2016; 10:3149-3157
110. 2 Nanoparticle Treatment Induces Controlled ROS-mediated Autophagy and Terminal Differentiation of Leukemia Cells. Sci Rep. 2016; 6:34413
111. Shi Z, Huang X, Liu B, Tao H, Cai Y, Tang R. Biological response of osteosarcoma cells to size-controlled nanostructured hydroxyapatite. J Biomater Appl. 2010; 25:19-37
112. Tran PA, Sarin L, Hurt RH, Webster TJ. Titanium surfaces with adherent selenium nanoclusters as a novel anticancer orthopedic material. J Biomed Mater Res A. 2010; 93:1417-1428
113. Ruoslahti E, Pierschbacher MD. New perspectives in cell adhesion: RGD and integrins. Science. 1987; 238:491-497
114. Yuan A, Yang B, Wu J, Hu Y, Ming X. Dendritic nanoconjugates of photosensitizer for targeted photodynamic therapy. Acta Biomater. 2015; 21:63-73
115. Liu L, Fu L, Jing T, Ruan Z,Yan L. pH-Triggered Polypeptides Nanoparticles for Efficient BODIPY Imaging-Guided Near Infrared Photodynamic Therapy. ACS Appl Mater Interfaces. 2016; 8:8980-8990
116. Yao X, Chen L, Chen X, Xie Z, Ding J, He C, Zhang J, Chen X. pH-responsive metallo-supramolecular nanogel for synergistic chemo-photodynamic therapy. Acta Biomater. 2015; 25:162-171
117. Ge P, Sheng F, Jin Y, Tong L, Du L, Zhang L, Tian N, Li G. Magnetic resonance imaging of osteosarcoma using a bis(alendronate)-based bone-targeted contrast agent. Biomed Pharmacother. 2016; 84:423-429
118. Ohba T, Cates JM, Cole HA, Slosky DA, Haro H, Ichikawa J, Ando T, Schwartz HS, Schoenecker JG. Pleiotropic effects of bisphosphonates on osteosarcoma. Bone. 2014; 63:110-120
119. McClung M, Clemmesen B, Daifotis A, Gilchrist NL, Eisman J, Weinstein RS, Fuleihan Ge-H, Reda C, Yates AJ, Ravn P. Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Alendronate Osteoporosis Prevention Study Group. Ann Intern Med. 1998; 128:253-261
120. Wang H, Liu J, Tao S, Chai G, Wang J, Hu FQ, Yuan H. Tetracycline-grafted PLGA nanoparticles as bone-targeting drug delivery system. Int J Nanomedicine. 2015; 10:5671-5685
121. Woodbury DH, Beierwaltes WH. Fluorine-18 uptake and localization in soft tissue deposits of osteogenic sarcoma in rat and man. J Nucl Med. 1967; 8:646-651
122. Campanile C, Arlt MJ, Kramer SD, Honer M, Gvozdenovic A, Brennecke P, Fischer CR, Sabile AA, Muller A, Ametamey SM, Born W, Schibli R, Fuchs B. Characterization of different osteosarcoma phenotypes by PET imaging in preclinical animal models. J Nucl Med. 2013; 54:1362-1368
123. Wang HQ, Batentschuk M, Osvet A, Pinna L, Brabec CJ. Rare-earth ion doped up-conversion materials for photovoltaic applications. Adv Mater. 2011; 23:2675-2680
124. Nyk M, Kumar R, Ohulchanskyy TY, Bergey EJ, Prasad PN. High contrast in vitro and in vivo photoluminescence bioimaging using near infrared to near infrared upconversion in Tm3+ and Yb3+ doped fluoride nanophosphors. Nano Lett. 2008; 8:3834-3838
125. Du B, Han S, Zhao F, Lim KH, Xi H, Su X, Yao H, Zhou J. A smart upconversion-based light-triggered polymer for synergetic chemo-photodynamic therapy and dual-modal MR/UCL imaging. Nanomedicine. 2016
126. 3:Yb,Er nanoparticles with bright three-photon up-conversion fluorescence under near-infrared light. Dalton Trans. 2015; 44:16081-16090
127. Zeng L, Luo L, Pan Y, Luo S, Lu G, Wu A. In vivo targeted magnetic resonance imaging and visualized photodynamic therapy in deep-tissue cancers using folic acid-functionalized superparamagnetic-upconversion nanocomposites. Nanoscale. 2015; 7:8946-8954
128. Park YI, Kim HM, Kim JH, Moon KC, Yoo B, Lee KT, Lee N, Choi Y, Park W, Ling D, Na K, Moon WK, Choi SH, et al. Theranostic probe based on lanthanide-doped nanoparticles for simultaneous in vivo dual-modal imaging and photodynamic therapy. Adv Mater. 2012; 24:5755-5761
129. Chatterjee DK and Yong Z. Upconverting nanoparticles as nanotransducers for photodynamic therapy in cancer cells. Nanomedicine (Lond). 2008; 3:73-82
130. Mi C, Wu J, Yang Y, Han B, Wei J. Efficient upconversion luminescence from Ba5Gd8Zn4O21:Yb(3+), Er(3+) based on a demonstrated cross-relaxation process. Sci Rep. 2016; 6:22545
131. Pushie MJ, Pickering IJ, Korbas M, Hackett MJ, George GN. Elemental and chemically specific X-ray fluorescence imaging of biological systems. Chem Rev. 2014; 114:8499-8541
132. Zou X, Yao M, Ma L, Hossu M, Han X, Juzenas P, Chen W. X-ray-induced nanoparticle-based photodynamic therapy of cancer. Nanomedicine (Lond). 2014; 9:2339-2351
133. Hashiguchi S, Kusuzaki K, Murata H, Takeshita H, Hashiba M, Nishimura T, Ashihara T,Hirasawa Y. Acridine orange excited by low-dose radiation has a strong cytocidal effect on mouse osteosarcoma. Oncology. 2002; 62:85-93
134. Mordon S, Cochrane C, Tylcz JB, Betrouni N, Mortier L, Koncar V. Light emitting fabric technologies for photodynamic therapy. Photodiagnosis Photodyn Ther. 2015; 12:1-8
135. Garcez AS, Fregnani ER, Rodriguez HM, Nunez SC, Sabino CP, Suzuki H, Ribeiro MS. The use of optical fiber in endodontic photodynamic therapy. Is it really relevant? Lasers Med Sci. 2013; 28:79-85
136. Fimple JL, Fontana CR, Foschi F, Ruggiero K, Song X, Pagonis TC, Tanner AC, Kent R, Doukas AG, Stashenko PP,Soukos NS. Photodynamic treatment of endodontic polymicrobial infection in vitro. J Endod. 2008; 34:728-734
137. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol. 2002; 20:709-760
138. Xia Y, Gupta GK, Castano AP, Mroz P, Avci P, Hamblin MR. CpG oligodeoxynucleotide as immune adjuvant enhances photodynamic therapy response in murine metastatic breast cancer. J Biophotonics. 2014; 7:897-905
139. Korbelik M, Cecic I. Enhancement of tumour response to photodynamic therapy by adjuvant mycobacterium cell-wall treatment. J Photochem Photobiol B. 1998; 44:151-158
140. Korbelik M, Sun J, Posakony JJ. Interaction between photodynamic therapy and BCG immunotherapy responsible for the reduced recurrence of treated mouse tumors. Photochem Photobiol. 2001; 73:403-409
141. Frampton JE. Mifamurtide: a review of its use in the treatment of osteosarcoma. Paediatr Drugs. 2010; 12:141-153
142. Creaven PJ, Cowens JW, Brenner DE, Dadey BM, Han T, Huben R, Karakousis C, Frost H, LeSher D, Hanagan J. Initial clinical trial of the macrophage activator muramyl tripeptide-phosphatidylethanolamine encapsulated in liposomes in patients with advanced cancer. J Biol Response Mod. 1990; 9:492-498
143. Kleinerman ES, Jia SF, Griffin J, Seibel NL, Benjamin RS, Jaffe N. Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration. J Clin Oncol. 1992; 10:1310-1316
144. Kleinerman ES, Gano JB, Johnston DA, Benjamin RS, Jaffe N. Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma. Am J Clin Oncol. 1995; 18:93-99
145. Asano T, McWatters A, An T, Matsushima K, Kleinerman ES. Liposomal muramyl tripeptide upregulates interleukin-1 alpha, interleukin-1 beta, tumor necrosis factor-alpha, interleukin-6 and interleukin-8 gene expression in human monocytes. J Pharmacol Exp Ther. 1994; 268:1032-1039
146. Korbelik M. Cancer vaccines generated by photodynamic therapy. Photochem Photobiol Sci. 2011; 10:664-669
147. Gollnick SO, Vaughan L, Henderson BW. Generation of effective antitumor vaccines using photodynamic therapy. Cancer Res. 2002; 62:1604-1608
148. Korbelik M, Merchant S. Photodynamic therapy-generated cancer vaccine elicits acute phase and hormonal response in treated mice. Cancer Immunol Immunother. 2012; 61:1387-1394
149. Korbelik M, Stott B, Sun J. Photodynamic therapygenerated vaccines: relevance of tumour cell death expression. Br J Cancer. 2007; 97:1381-1387
150. Korbelik M, Banath J, Saw KM, Zhang W, Ciplys E. Calreticulin as cancer treatment adjuvant: combination with photodynamic therapy and photodynamic therapy-generated vaccines. Front Oncol. 2015; 5:15
151. Sotiriou E, Apalla Z, Vrani F, Lallas A, Chovarda E, Ioannides D. Photodynamic therapy vs. imiquimod 5% cream as skin cancer preventive strategies in patients with field changes: a randomized intraindividual comparison study. J Eur Acad Dermatol Venereol. 2015; 29:325-329
152. Ibbotson SH, Ferguson J. Ambulatory photodynamic therapy using low irradiance inorganic light-emitting diodes for the treatment of non-melanoma skin cancer: an open study. Photodermatol Photoimmunol Photomed. 2012; 28:235-239